Charlotte's Web Moves to Phase 2 FDA Trial for Autism Treatment with DeFloria Charlotte's Web has received FDA approval to advance DeFloria's clinical trial for AJA001, targeting autism symptoms. This innovative treatment shows promise.

Charlotte's Web Moves to Phase 2 FDA Trial for Autism Treatment with DeFloria #United_States #Louisville #AJA001 #Charlotte's_Web #Autism_Treatment

DeFloria's AJA001 Gains FDA Approval for Phase II Trial Targeting Autism Spectrum Disorder DeFloria's AJA001, an oral cannabinoid drug for Autism Spectrum Disorder, has received FDA clearance for Phase 2 trials, aiming to address treatment gaps.

DeFloria's AJA001 Gains FDA Approval for Phase II Trial Targeting Autism Spectrum Disorder #United_States #Autism #Littleton #DeFloria #AJA001

Charlotte's Web Shares Significant Phase 1 Results for Autism Treatment Drug AJA001 Charlotte's Web announces promising Phase 1 results for AJA001, aimed at treating autism spectrum disorder symptoms, showcasing significant potential.

Charlotte's Web Shares Significant Phase 1 Results for Autism Treatment Drug AJA001 #United_States #Louisville #AJA001 #Charlotte's_Web #CBD

DeFloria Unveils Promising Phase 1 Results for AJA001 in Autism Treatment DeFloria's Phase 1 trial results for AJA001 show safety and efficacy for autism spectrum disorder treatment, paving the way for future studies.

DeFloria Unveils Promising Phase 1 Results for AJA001 in Autism Treatment #United_States #DeFloria #AJA001 #Autism_Spectrum_Disorder #Littleton,_Colorado